2 unknown, 1 withdrawn. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 2, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Shi Ming: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin - Intrahepatic Cholangiocarcinoma | Phase 3 | Unknown | Shi Ming | 188 | 2021-07-09 | 2021-07-14 |
| Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection Lenvatinib, Nivolumab - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Withdrawn | Shi Ming | 2019-10-30 | 2020-01-09 | |
| HAIC Versus Systemic Chemotherapy for Unresectable ICC irinotecan, oxaliplatin , fluorouracil, and leucovorin, gemcitabine and oxaliplatin - Intrahepatic Cholangiocarcinoma | Phase 3 | Unknown | Shi Ming | 188 | 2018-08-01 | 2019-12-05 |
Cholangiocarcinoma (2) · Carcinoma, Hepatocellular (1) · Hepatitis B (1)
Fluorouracil (2) · Gemcitabine (2) · Leucovorin (2) · Oxaliplatin (2) · Cisplatin (1) · Irinotecan (1) · Nivolumab (1) · lenvatinib (1)
China (3)
Ming Shi, MD (2)